Vor Biopharma Inc. (NYSE:VOR) Given Average Rating of “Hold” by Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have been given a consensus rating of “Hold” by the ten ratings firms that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $7.06.

A number of equities research analysts have recently commented on VOR shares. Baird R W cut Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Stifel Nicolaus decreased their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Jones Trading downgraded shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Wedbush reiterated a “neutral” rating and issued a $0.40 price objective (down from $7.00) on shares of Vor Biopharma in a report on Thursday, May 8th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Vor Biopharma in a research report on Friday, May 9th.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds have recently modified their holdings of the company. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at approximately $33,000. Money Concepts Capital Corp lifted its holdings in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after acquiring an additional 26,535 shares during the last quarter. Virtu Financial LLC acquired a new position in Vor Biopharma in the fourth quarter valued at approximately $60,000. Goldman Sachs Group Inc. grew its position in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Vor Biopharma during the fourth quarter worth $80,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Performance

VOR stock opened at $0.22 on Tuesday. Vor Biopharma has a one year low of $0.13 and a one year high of $1.80. The firm’s fifty day moving average is $0.43 and its 200 day moving average is $0.88. The firm has a market cap of $27.85 million, a PE ratio of -0.14 and a beta of -0.51.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.